Advertisement

Phase I Clinical Trial of Locoregional Administration of the Oncolytic Adenovirus ONYX-015 in Combination with Mitomycin-C, Doxorubicin, and Cisplatin Chemotherapy in Patients with Advanced Sarcomas

  • Mateusz Opyrchal
  • Ileana Aderca
  • Evanthia GalanisEmail author
Protocol
Part of the Methods in Molecular Biology™ book series (MIMB, volume 542)

Summary

Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There ia an need for more efficient and less toxic treatments is this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.

Keywords

Cisplatin chemotherapy doxorubicin mitomycin-C oncolytic adenovirus ONYX-015 sarcomas 

References

  1. 1.
    Baker, J. C., Smale, S. T., Tjian, R., and Ames, B. N. (1987) Inhibition of simian virus 40 DNA replication in vitro by poly(ADP-ribosyl)ated diadenosine tetraphosphate. J. Biol. Chem. 262, 14855–8.Google Scholar
  2. 2.
    Dobner, T., Horikoshi, N., Rubenwolf, S., and Shenk, T. (1996) Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science. 272, 1470–3.PubMedCrossRefGoogle Scholar
  3. 3.
    Yew, P. R., and Berk, A. J. (1992) Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature. 357, 82–5.PubMedCrossRefGoogle Scholar
  4. 4.
    Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. (1996) An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 274, 373–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Turnell, A. S., Grand, R. J., and Gallimore, P. H. (1999) The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status. J. Virol. 73, 2074–83.Google Scholar
  6. 6.
    Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M., and zur Hausen, H. (1998) Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J. Virol. 72, 9470–8.Google Scholar
  7. 7.
    Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D. D., and Kirn, D. H. (1997) ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639–45.Google Scholar
  8. 8.
    Kirn, D. (2001) Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 8, 89–98.PubMedCrossRefGoogle Scholar
  9. 9.
    Ganly, I., Kirn, D., Eckhardt, G., Rodriguez, G. I., Soutar, D. S., Otto, R., Robertson, A. G., Park, O., Gulley, M. L., Heise, C., Von Hoff, D. D., and Kaye, S. B. (2000) A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798–806.Google Scholar
  10. 10.
    Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Tong, A., Randlev, B., Olson, S., and Kirn, D. (2001) Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther. 8, 746–59.PubMedCrossRefGoogle Scholar
  11. 11.
    Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C., Uprichard, M., Hatfield, M., Rome, L., Rubin, J., and Kirn, D. (2002) Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res. 62, 6070–9.PubMedGoogle Scholar
  12. 12.
    Vasey, P. A., Shulman, L. N., Campos, S., Davis, J., Gore, M., Johnston, S., Kirn, D. H., O'Neill, V., Siddiqui, N., Seiden, M. V., and Kaye, S. B. (2002) Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20, 1562–9.CrossRefGoogle Scholar
  13. 13.
    Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S., and Kirn, D. (2000) Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359–66.PubMedGoogle Scholar
  14. 14.
    Hecht, J. R., Bedford, R., Abbruzzese, J. L., Lahoti, S., Reid, T. R., Soetikno, R. M., Kirn, D. H., and Freeman, S. M. (2003) A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 9, 555–61.Google Scholar
  15. 15.
    Hamid, O., Varterasian, M. L., Wadler, S., Hecht, J. R., Benson, A., 3rd, Galanis, E., Uprichard, M., Omer, C., Bycott, P., Hackman, R. C., and Shields, A. F. (2003) Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J. Clin. Oncol. 21, 1498–504.CrossRefGoogle Scholar
  16. 16.
    Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., and Kirn, D. H. (2000) A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879–85.Google Scholar
  17. 17.
    Xia, Z. J., Chang, J. H., Zhang, L., Jiang, W. Q., Guan, Z. Z., Liu, J. W., Zhang, Y., Hu, X. H., Wu, G. H., Wang, H. Q., Chen, Z. C., Chen, J. C., Zhou, Q. H., Lu, J. W., Fan, Q. X., Huang, J. J., and Zheng, X. (2004) [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus.]. Ai. Zheng. 23, 1666–70.Google Scholar
  18. 18.
    Hung, J., and Anderson, R. (1997) p53: functions, mutations and sarcomas. Acta Orthop Scand Suppl 273, 68–73.PubMedGoogle Scholar
  19. 19.
    Seki, A., Kodama, J., Miyagi, Y., Kamimura, S., Yoshinouchi, M., and Kudo, T. (1997) Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas. Int. J. Cancer. 73, 33–7.Google Scholar
  20. 20.
    Simon, R., Freidlin, B., Rubinstein, L., Arbuck, S. G., Collins, J., and Christian, M. C. (1997) Accelerated titration designs for phase I clinical trials in oncology. J. Natl. Cancer Inst. 89, 1138–47.CrossRefGoogle Scholar
  21. 21.
    Galanis, E., Okuno, S. H., Nascimento, A. G., Lewis, B. D., Lee, R. A., Oliveira, A. M., Sloan, J. A., Atherton, P., Edmonson, J. H., Erlichman, C., Randlev, B., Wang, Q., Freeman, S., and Rubin, J. (2005) Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 12, 437–45.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Mateusz Opyrchal
  • Ileana Aderca
  • Evanthia Galanis
    • 1
    Email author
  1. 1.Division of Medical OncologyMayo ClinicRochesterUSA

Personalised recommendations